Directory
>
Christopher Ford
Christopher Ford
Senior Vice President, R&D | Seres Therapeutics
Cambridge, Massachusetts, United States
Christopher Ford
Summary
Christopher Ford is a highly accomplished Senior Vice President of Translational Biology at Seres Therapeutics, specializing in microbiome therapeutics aimed at combating infectious diseases. With a PhD from Harvard University, he has a strong foundation in infectious disease and immunology, evidenced by his innovative work on drug-resistant tuberculosis and host-pathogen interactions. Christopher has led significant programs, including the successful acquisition of a CARB-X contract to support the development of SER-155. His research has paved the way for advancements in understanding the microbiome's role in health and disease. He has a rich history of collaboration with prestigious institutions like the Broad Institute, where he developed novel techniques to study pathogen evolution. Christopher's leadership in the field is complemented by numerous awards and publications, reflecting his commitment to advancing scientific knowledge and therapeutic solutions.
Christopher Ford
Work Experience
Senior Vice President, R&D at
Seres Therapeutics
July 2024 - Present
Vice President, Translational Biology at
Seres Therapeutics
January 2022 - August 2024
Senior Director, Computational Microbiome Sciences at
Seres Therapeutics
January 2020 - February 2022
Program Lead, SER-301 & SER-155 at
Seres Therapeutics
February 2019 - February 2022
Program Lead, SER-155 at
Seres Therapeutics
January 2017 - August 2020
Director, Microbiome Sciences at
Seres Therapeutics
November 2018 - January 2020
Group Leader, Microbiome Sciences at
Seres Therapeutics
August 2017 - November 2018
Senior Scientist, Microbiome Sciences at
Seres Therapeutics
September 2015 - August 2017
Postdoctoral Fellow at
Broad Institute of MIT and Harvard
November 2013 - September 2015
Post Doctoral Researcher, Regev Lab at
Broad Institute of MIT and Harvard
January 2013 - November 2013
Postdoctoral Fellow (Visiting Scientist) at
Harvard School Of Public Health
September 2012 - January 2013
Graduate Research Fellow at
Harvard University School Of Public Health
August 2007 - September 2012
Coordinator at
Boston Tb
January 2009 - January 2011
Head Resident at
Residence Life College Of W And M
August 2006 - May 2007
Certified Pharmacy Technician at
Sentar Inc.
September 2003 - April 2007
Resident Assistant at
Residence Life College Of W And M
August 2005 - August 2006
Medical Assistant & Grant Coordinator at
Norge Primary Care Angels Of Mercy
September 2002 - July 2003
Christopher Ford
Education
Harvard University School of Public health , Phd
January 2007 - January 2012
William and Mary, Ma
January 2006 - January 2007
William and Mary, Bs
January 2002 - January 2006
Frequently Asked Questions about Christopher Ford
What is Christopher Ford email address?
Christopher Ford's primary email address is *****@serestherapeutics.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Christopher Ford work for?
Christopher Ford is a Senior Vice President, R&D at Seres Therapeutics, a company specializing in Commercial physical research.
Where Christopher Ford graduated from?
Christopher Ford holds a degree in Infectious Disease And Immunology from Harvard University School of Public health .
How can I directly contact Christopher Ford?
To contact Christopher Ford directly, you can use the email address *****@serestherapeutics.com. Complete contact information is available upon registration with Muraena.
Who is Christopher Ford?
Christopher Ford is a highly accomplished Senior Vice President of Translational Biology at Seres Therapeutics, specializing in microbiome therapeutics aimed at combating infectious diseases. With a PhD from Harvard University, he has a strong foundation in infectious disease and immunology, evidenced by his innovative work on drug-resistant tuberculosis and host-pathogen interactions. Christopher has led significant programs, including the successful acquisition of a CARB-X contract to support the development of SER-155. His research has paved the way for advancements in understanding the microbiome's role in health and disease. He has a rich history of collaboration with prestigious institutions like the Broad Institute, where he developed novel techniques to study pathogen evolution. Christopher's leadership in the field is complemented by numerous awards and publications, reflecting his commitment to advancing scientific knowledge and therapeutic solutions.
Christopher`s contact details
*****@serestherapeutics.com
Colleagues
Chief Medical Officer
President, Chief Executive Officer
VP Medical Affairs
Founder & Owner
Senior Vice President & Chief Information Officer
Executive Director, Clinical Operations